Wegovy is the semaglutide product carrying the weight-management indications, and Zepbound is the tirzepatide equivalent
Clinical Evidence So Far When reviewing studies on depression outcomes associated with GLP1 treatment , the evidence remains preliminary and inconclusive
Weekly Group Coaching Sessions: Our weekly group coaching sessions cover essential aspects of health and wellness, including nutrition, mindset, and movement coaching
Tirzepatide (Mounjaro, Zepbound): GLP-1 and GIP receptors
Other GLP-1/GIP/GCG Triple Agonists in Development Besides retatrutide, several GLP-1/GIP/GCG triple agonists are in early-stage clinical trials (Table 3), though the WL efficacy associated with these medications remains unknown
JAMA Internal Medicine , v